Blood Cancer Drugs Market Report 2024: Strategies And Recent Developments | Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Blood Cancer Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The blood cancer drugs market size has grown strongly in recent years. It will grow from $69.16 billion in 2023 to $74.77 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to advancements in research and development, aging population, increased awareness and early diagnosis, regulatory approvals.

The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $100.9 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing disease prevalence, emerging markets, supportive care. Major trends in the forecast period include research and development investments, combination therapies, biomarker identification, immunotherapy advancements, personalized medicine.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Market Segmentation:
The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/Mabthera (rituximab), Gleevec/Glivec (imatinib), Revlimid (lenalidomide), Velcade (bortezomib), Tasigna (nilotinib), pomalyst (pomalidomide), Fidanza (azacitidine), kyphosis (carfilzomib), advertise (brentuximabvedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic.

Major Driver - Rising Incidence And Mortality Rates To Drive Market Growth
The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma, and others have different risk factors some can be controlled or prevented through drug therapies and others may lead to death. According to the Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases from myeloma. Furthermore, the report estimated, that in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000The increasing number of deaths and the increasing incidence of blood cancer cases globally drive the blood cancer drug market.

Competitive Landscape:
Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Top Trend - Increasing Adoption Of Ai Technology Revolutionizes Blood Cancer Drug Development
Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer, and Johnson and Johnson have already invested in AI technologies to reduce the time taken and costs incurred for drug development. For instance, Johnson and Johnson agreed with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Blood Cancer Drugs Market Characteristics
3. Blood Cancer Drugs Market Trends And Strategies
4. Blood Cancer Drugs Market - Macro Economic Scenario
5. Blood Cancer Drugs Market Size And Growth
…..
27. Blood Cancer Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.